Product Description
Human serum albumin fused to the N-terminus of growth hormone (Sourced from: https://chem.nlm.nih.gov/chemidplus/rn/1613273-96-3)
Mechanisms of Action: Growth Hormone Analogue
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Teva
Company Location: PETACH TIKVA L3 49131
Company CEO: Kåre Schultz
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hypopituitarism|Dwarfism, Pituitary|Pituitary Diseases|Deficiency Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| TV1106-IMM-20001 | P2 |
Terminated |
Hypopituitarism|Dwarfism, Pituitary |
2016-04-30 |
2019-03-20 |
Treatments |
|
| 2013-004468-69 | P2 |
Terminated |
Hypopituitarism |
2016-04-29 |
2022-03-13 |
Treatments |
|
| 2012-004975-37 | P2 |
Completed |
Hypopituitarism |
2015-06-22 |
2025-06-25 |
Treatments |
|
| TV1106-GHD-201 | P2 |
Completed |
Hypopituitarism|Pituitary Diseases|Dwarfism, Pituitary|Deficiency Diseases |
2013-08-05 |
2021-12-11 |
Primary Endpoints |
|
| 2014-002736-13 | P3 |
Terminated |
Hypopituitarism |
2017-08-19 |
2022-03-13 |
Treatments |
|
| TV1106-IMM-30022 | P3 |
Terminated |
Dwarfism, Pituitary|Pituitary Diseases|Deficiency Diseases|Hypopituitarism |
2016-02-29 |
2021-12-11 |
Primary Endpoints|Treatments |
|
| TV1106-IMM-30021 | P3 |
Terminated |
Hypopituitarism |
2015-12-31 |
2022-01-22 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
|
| 2014-003796-32 | P3 |
Terminated |
Hypopituitarism |
2015-12-18 |
2022-03-13 |
Recent News Events
Date |
Type |
Title |
|---|